Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganoderma lucidum spore + chemotherapy
- Development stage
- Unknown
- Lead developer
- Gao Yajie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves the use of Ganoderma lucidum spore powder as an adjuvant to standard chemotherapy (specifically gemcitabine or cisplatin) for the treatment of non-small cell lung carcinoma (NSCLC). Ganoderma lucidum, a medicinal mushroom also known as Reishi or Lingzhi, contains bioactive compounds such as polysaccharides and triterpenes that are thought to possess immunomodulatory, antioxidant, and antineoplastic properties. In this clinical context, the spores are administered orally to potentially enhance the therapeutic efficacy of chemotherapy while mitigating common toxicities, including bone marrow suppression and gastrointestinal mucosal damage. The intervention is currently being evaluated in a Phase 2 randomized, placebo-controlled trial led by Gao Yajie at The First Affiliated Hospital of Dalian Medical University to assess its impact on quality of life and various biochemical markers of oxidative stress and inflammation.
- Other names
- Ganoderma lucidum spore powderReishi mushroom spore powderLingzhi spore powder
02
Targets
DDR (DNA damage response)
Beyond the preview
Go deeper on Ganoderma lucidum spore + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganoderma lucidum spore + chemotherapy.